| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S7923 R23972 |
Stephansson, 2013 | Stillbirth (after 22 weeks of gestation) | 3 months (or more) before pregnancy or during pregnancy excluded | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: No Monotherapy: no or not specified |
1.67 [1.21;2.31] C excluded (exposition period) |
37/6,013 5,919/1,604,649 | 5,956 | 6,013 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S7194 R20417 |
Colvin, 2011 | Stillbirths | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No Monotherapy: substance alone among the specific class of antidep (SSRI, SNRI, ...) | 0.83 [0.21;3.35] | -/371 612/94,561 | - | 371 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6733 R19031 |
Diav-Citrin, 2008 | Stillbirth | during pregnancy (anytime or not specified) | prospective cohort | unexposed (general population or NOS) | Adjustment: No Monotherapy: no or not specified | 0.53 [0.07;4.24] C | 1/346 8/1,467 | 9 | 346 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S15005 R61451 |
Chambers, 1996 | Stillbirth | late pregnancy | prospective cohort | unexposed (general population or NOS) | Adjustment: No Monotherapy: no or not specified | 1.73 [0.15;19.31] C | 1/74 2/254 | 3 | 74 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 3 studies | 0.85 [0.30;2.40] | 12 | 791 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded